Welcome to our dedicated page for Xencor SEC filings (Ticker: XNCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xencor, Inc. (XNCR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, Xencor uses its SEC filings to report material events, financial results and key corporate developments related to its XmAb® technology platform and pipeline.
Investors can review Form 8-K filings in which Xencor reports quarterly financial results, such as revenue from collaborations, milestones and royalties, research and development expenses, and cash and marketable securities balances. These filings often incorporate press releases that summarize progress in clinical programs like XmAb819, XmAb541, plamotamab, XmAb657, XmAb942 and XmAb412, as well as updates on partnered programs and royalty-bearing products.
Xencor’s SEC filings also cover corporate actions and governance changes, including board appointments and director compensation, and Regulation FD disclosures related to investor presentations and webcasts. For example, the company has filed 8-Ks to furnish presentation materials and press releases discussing initial Phase 1 results of XmAb819 and early data from XmAb541, along with associated clinical timelines.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in each document, helping readers quickly understand the implications of new information. Users can monitor real-time updates from EDGAR, track items related to financial condition, material clinical data disclosures, and governance events, and use the structured view of XNCR filings to follow how Xencor’s antibody engineering business and pipeline are reflected in its regulatory reporting.
XNCR reports an insider notice to sell 3,244 common shares related to Restricted Stock Vesting scheduled 03/04/2026.
The filing also shows a prior sale of 1,492 common shares on 03/03/2026 by Celia E. Eckert, listed in the three‑month sales section.
Company Form 144 discloses insider transactions in common stock. The filing lists a restricted stock vesting of 14,870 shares on 03/04/2026 attributed to the issuer as compensation and reports two sales by Bassil I. Dahiyat: 114,377 shares on 12/19/2025 for $1,796,942.73 and 6,758 shares on 03/03/2026 for $80,387.09.
XNCR Form 144 discloses a proposed sale of 4,118 common shares tied to restricted stock vesting, listed as an issuer compensation transfer effective 03/04/2026. The filing also reports prior sales by John Desjarlais: 73,367 shares for $11,534,819.99 on 12/19/2025 and 2,663 shares for $31,676.65 on 03/03/2026.
Xencor Inc. senior vice president and chief scientific officer John R. Desjarlais reported a mix of stock sales and equity awards. He sold 2,663 shares of common stock on March 3, 2026 at $11.8951 per share, with a footnote stating the sale was to pay withholding taxes on the vesting of 6,253 restricted stock units.
On March 2, 2026, he received a grant of 24,907 shares of common stock in the form of restricted stock units that vest in three equal annual installments, subject to continued service. He also received a stock option for 149,440 shares, vesting 25% one year after March 2, 2026 and the remainder monthly over the following three years, also contingent on continued service.
Xencor Inc reported that Senior Vice President and CFO Bart Jan Cornelissen received new equity awards. He was granted stock options for 116,750 shares of common stock at an exercise price of $0.00 per share, vesting over four years starting one year after March 2, 2026. He also acquired 19,458 restricted stock units that vest in three equal annual installments on the first, second, and third anniversaries of the grant date, contingent on continued service. Following these grants, he directly holds 81,914 shares of common stock.
Xencor Inc senior vice president and general counsel Celia Eckert reported new equity awards and a small tax-related share sale. She received a grant of 18,680 restricted stock units that vest in three equal annual installments, assuming she continues serving the company through each vesting date.
She was also granted options to buy 112,080 shares, with 25% vesting one year after March 2, 2026 and the rest vesting monthly so the option is fully vested after four years. On March 3, 2026, she sold 1,492 common shares at $11.8951 each to cover withholding taxes on 3,502 vested restricted stock units, and held 81,929 common shares directly afterward.
Xencor Inc President and CEO Bassil I. Dahiyat reported a mix of equity grants and a small share sale. He received a grant of 583,748 stock options and 97,291 restricted stock units, both at no cost, increasing his direct awards-based exposure to the company.
The restricted stock units vest in thirds on the first, second, and third anniversaries of the grant date, while the options vest over four years starting from March 2, 2026. Dahiyat also sold 6,758 common shares at an average price of $11.8951 per share to pay withholding taxes related to the vesting of 17,507 restricted stock units, and directly held 567,792 common shares after the sale.
Xencor, Inc. disclosed that Alexion Pharmaceuticals, the licensee for Ultomiris, has taken the position that it does not owe any additional royalties on U.S. sales of Ultomiris and does not intend to make future U.S. royalty payments under their Option and License Agreement. Alexion told Xencor it will continue paying royalties on sales outside the United States, and Xencor strongly disagrees with Alexion’s position and is evaluating its options.
Xencor had previously expected an estimated additional $100–$120 million in low single-digit U.S. Ultomiris royalties through 2028 based on a recently issued U.S. patent. Despite this potential loss of anticipated revenue, Xencor now expects to end 2026 with $380–$400 million in cash, cash equivalents and marketable debt securities and believes this will fund its research and operations into mid‑2028.
XNCR reported a Form 144 notice to sell of 6,758 common shares tied to restricted stock vesting on 03/02/2026. The filing shows these shares are held by Fidelity Brokerage Services LLC and are linked to compensation.
The excerpt also reports a prior disposition of 114,377 common shares by Bassil I. Dahiyat on 12/19/2025; the filing is a regulatory notice of proposed sales under the securities rules.